麗珠醫藥集團股份有限公司 Livzon Pharmaceutical Group Inc.* 董事會（「董事會」） 成 員載列如下： 執行董事 現任董事在董事會及各委員會的任職情況 董事會設立五個委員會。下表提供各董事會成員在這些委員會中所擔任的職位。 | | 審計委員會 | 薪酬與 | 提名委員會 | 戰略委員會 | 環境、社會及 | | --- | --- | --- | --- | --- | --- | | | | 考核委員會 | | | 管治委員會 | | 朱保國先生 | | | | C | C | | 唐陽剛先生 | | M | | M | M | | 陶德勝先生 | | | M | M | | | 白華先生 | C | M | | | M | | 羅會遠先生 | M | | C | | | | 崔麗婕女士 | M | C | M | | M | | 王智瑶女士 | | | | | M | 附注： 唐陽剛先生 （總裁） 徐國祥先生 （副董事長及副總裁） 非執行董事 朱保國先生 （董事長） 陶德勝先生 （副董事長） 林楠棋先生 邱慶豐先生 職工代表董事 冉咏梅女士 獨立非執行董事 白華先生 羅會遠先 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不發表 任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任 何責任。 於二零二五年十二月十日舉行之 二零二五年第一次臨時股東大會 投票表決結果 茲提述麗珠醫藥集團股份有限公司Livzon Pharmaceutical Group Inc.*（「本公司」）日期為二零二五年 十一月十一日的通函（「該通函」）。除文義另有規定外，本公告所用詞彙與通函所界定者具有相同 涵義。 本公司董事會（「董事會」）茲宣佈，本公司已於二零二五年十二月十日在中國廣東省珠海市金灣區 創業北路38號總部大樓六樓會議室舉行二零二五年第一次臨時股東大會（「臨時股東大會」或「大 會」），所有列載於召開大會的通知內擬提呈大會之決議案已獲本公司股東以投票方式表決通過。 於大會上審議之議案之詳細內容，載列於該通函。 於大會記錄日期當日（即二零二五年十二月三日），本公司已發行的股份（「股份」）總數為 887,907,171 股（不含已回購未註銷的股份），其中 588,100,054 股為 A 股及 299,807, ...

Core Viewpoint - Lijun Group (000513.SZ) announced that it has 194 products included in the National Medical Insurance Directory for 2025, which is expected to positively impact the company's operating performance in the future [1] Group 1: Product Inclusion - The group has 194 products in the National Medical Insurance Directory, including 92 Class A and 102 Class B products [1] - Injectable Aripiprazole microspheres have been included in the National Medical Insurance Directory for the first time through negotiations [1] - Injectable Triptorelin acetate microspheres have a new indication added, and Injectable Esomeprazole sodium has successfully renewed its contract [1] - No products from the group have exited the National Medical Insurance Directory [1] Group 2: Market Impact - The inclusion of these products in the National Medical Insurance Directory is expected to help expand the market and improve drug accessibility [1] - The new version of the National Medical Insurance Directory will be officially implemented on January 1, 2026, and is not expected to have a significant impact on the company's current operating performance [1]

Group 1 - The core announcement is that 194 products from the company have been included in the National Medical Insurance Directory for 2025, consisting of 92 Class A and 102 Class B products [1] - Notable inclusions are the injectable Aripiprazole microspheres, which are newly negotiated for inclusion, and the injectable Triptorelin acetate microspheres, which have a new indication added [1] - The company expects that the inclusion of these products will help expand market access and improve drug availability, positively impacting future operating performance [1] Group 2 - The new version of the National Medical Insurance Directory will be officially implemented on January 1, 2026, and is not expected to have a significant impact on the company's current operating performance [1] - There are no products from the company that have exited the National Medical Insurance Directory [1]

（文章来源：证券日报） 证券日报网讯 12月8日，健康元在互动平台回答投资者提问时表示，公司间接持有新元素药业的股权比 例较小，对公司整体财务状况不构成重大影响。丽珠集团对其投资详情及新元素药业上市进展、具体时 间表，请分别以丽珠集团及新元素药业的官方披露信息为准。 ...

Group 1 - Cambridge Technology plans to invest 400 million yuan to establish a fund focused on optical devices and chips, aiming to invest in early-stage and growth-stage companies in the hard technology sector [1] - Tunnel Corporation's consortium won a bid for a highway project in Henan with a total investment of 6.49 billion yuan, using a BOT model for a 33.25-year cooperation period [2] - Hongrun Construction won a bid for a project worth 230 million yuan, which represents 3.88% of the company's projected revenue for 2024 [3] Group 2 - Tongrentang's product, Canling Baizhu Powder, received product registration approval from Health Canada, aimed at treating symptoms related to spleen and stomach weakness [4] - Hunan Baiyin announced a scheduled annual maintenance from December 9, 2025, to January 5, 2026, for equipment and facilities [5] - Changchun Gaoxin's subsidiary had two drugs included in the national medical insurance catalog for 2025 [6] Group 3 - Dongfang Securities' chairman resigned due to work relocation [7] - Xuantai Pharmaceutical's product, Sitagliptin Metformin Sustained-Release Tablets, was renewed for inclusion in the national medical insurance catalog [8] - ST Weihai was pre-selected for a smart agriculture EPC project with a bid of 652 million yuan, accounting for 26.27% of the company's projected revenue for 2024 [9] Group 4 - Guoxin Technology successfully tested an anti-quantum password financial POS chip, supporting both traditional and quantum-resistant algorithms [10] - Huaren Health's subsidiary received acceptance for a drug registration application for Lactulose Oral Solution, a common laxative [11] - Ankai Bus reported a 57.71% year-on-year increase in sales for the first 11 months of the year [12] Group 5 - Zhongyan Dadi's subsidiary won a bid for a project worth 73.86 million yuan [13] - Zhejiang Rongtai plans to invest 77 million USD in a factory in Thailand, focusing on mica paper and robot components production [14] - Optoelectronics plans to use up to 450 million yuan of idle funds for cash management [15] Group 6 - Tianyu Biological reported a 45.15% year-on-year decline in sales revenue from pig sales in November [16] - Daqin Railway's cargo transport volume increased by 1.75% year-on-year in November [17] - Yabo Co. won a bid for a heavy truck charging station project worth 3.616 million yuan [18] Group 7 - Hongri Pharmaceutical's product continues to be included in the national medical insurance catalog [19] - Jinggong Steel Structure signed a contract for steel structure installation worth approximately 470 million yuan for an overseas project [20] - Xizang Pharmaceutical's product, Xinhuasuan, continues to be included in the national medical insurance catalog [21] Group 8 - Guangdong Electric Power A announced the successful commissioning of a 1000MW unit at the Maoming Boge Power Plant [22] - Fuan Pharmaceutical's product, Palivizumab Injection, was newly included in the national medical insurance catalog [23] - Lizhu Group reported that 194 products were included in the 2025 national medical insurance catalog [24] Group 9 - Haisan Pharmaceutical's injection of Lantanol was included in the national medical insurance catalog [25] - Zhongtong Bus reported a 39.53% year-on-year increase in sales volume in November [26] - Shaanxi Coal Industry reported a 6.03% year-on-year increase in coal production in November [27] Group 10 - Haooubo's subsidiary received a medical device registration certificate for an IgG4 testing kit [28] - Yaopi Glass plans to invest 690 million yuan in new automotive glass production lines [30] - Huadian International completed the issuance of 2 billion yuan in medium-term notes [31] Group 11 - Zhongzai Zihuan's subsidiary won a bid for a green recycling project worth 205 million yuan [32] - Dabeinong reported a 25.26% year-on-year decline in sales revenue from pig sales in November [33] - Xiangjia Co. reported a 3.77% year-on-year increase in live poultry sales revenue in November [34] Group 12 - Huanxu Electronics reported a consolidated revenue of 5.198 billion yuan in November, a decrease of 3.34% year-on-year [35] - Aonong Biological reported a 72.21% year-on-year increase in pig sales volume in November [36] - Samsung Medical's subsidiary was pre-selected for a procurement project worth approximately 108 million yuan [37]

Core Viewpoint - The announcement by the company regarding the inclusion of 194 products in the National Medical Insurance Directory for 2025, which is a significant development for its product portfolio [1] Group 1: Product Inclusion - A total of 194 products from the company have been included in the National Medical Insurance Directory for 2025, consisting of 92 Class A and 102 Class B products [1] - The injectable Aripiprazole microspheres have been included in the National Medical Insurance Directory for the first time through negotiations [1] - The injectable Triptorelin acetate microspheres have a newly added indication, while the injectable Esomeprazole sodium has successfully renewed its contract [1]

Core Insights - The announcement from Lijun Pharmaceutical (01513) indicates that a total of 194 products from the company have been included in the National Medical Insurance Catalog for 2025, with 92 classified as Category A and 102 as Category B [1] Group 1 - The inclusion of Lijun Pharmaceutical's products in the National Medical Insurance Catalog is significant for the company's market positioning and revenue potential [1] - Notably, the injectable Aripiprazole microspheres have been included in the catalog for the first time through negotiations, which may enhance its market access [1] - The injectable Triptorelin acetate microspheres have received an additional indication, potentially expanding its usage and sales opportunities [1] Group 2 - The injectable Esomeprazole sodium has successfully renewed its contract, ensuring continued reimbursement and market presence [1]

自願公告 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性 亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚賴該等內容而引致 的任何損失承擔任何責任。 本集團未有產品退出《國家醫保目錄》。本集团前述產品納入《國家醫保目錄》有助於後 續擴大市場及提高藥品可及性，預計未來將對本公司的經營業績產生積極影響。此版《國 家醫保目錄》將於2026年1月1日正式執行，預計不會對本公司当期經營業績產生重大影響。 2 醫保支付標準、醫保報銷細則等相關資訊需以國家醫保局等相關部門公示的資訊為准。公 司產品未來銷售情況受醫藥行業政策變動、市場環境變化等影響，具有一定的不確定性。 敬請廣大投資者審慎決策，注意投資風險。 公司產品納入國家醫保目錄 麗珠醫藥集團股份有限公司Livzon Pharmaceutical Group Inc.*（「本公司」，連同其附屬公 司，統稱「本集團」）自願作出，以告知本公司股東及潛在投資者本集團最新業務更新。 2025年12月7日，國家醫保局、人力資源社會保障部發佈了《國家基本醫療保險、生育保 險和工傷保險藥品目錄（2025年）》（醫保 ...

以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 丽珠集团公告，2025年本集团共有194个产品纳入《国家医保目录》，含甲类92个、乙类102个。其中： 注射用阿立哌唑微球通过谈判首次纳入国家医保目录，注射用醋酸曲普瑞林微球新增适应症，注射用艾 普拉唑钠续约成功。 ...